In this free webinar, gain a strategic lens for building durable, scalable digital biomarker programs that deliver clinical and business…
Facility Growth Adds 30,000 Square Feet to Strengthen Warehouse, Cleanroom Production, and Office Capabilities ALPHARETTA, Ga., Oct. 16, 2025 /PRNewswire/…
LOS ANGELES, Oct. 15, 2025 /PRNewswire/ -- Women are twice as likely as men to develop Alzheimer's disease (AD) and multiple…
NEW YORK, Oct. 15, 2025 /PRNewswire/ -- The Global Digital Health Market is projected to grow from USD 288.55 billion in…
On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026 TRX319 is an allogeneic CAR-Tr1 Treg cell therapy…
– Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI®…
Distinguished cancer leader to advise BPGbio leadership on acceleration of NAi platform globally and BPM 31510 oncology franchise for Precision…
CONVOKE was the first and only pivotal trial to show a statistically significant reduction in experiential negative symptoms of schizophrenia…
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in…